Journal of Clinical & Experimental Pharmacology

The proton preparation NSC 631570: Immunomodulating effect of the anti-cancer preparation on basis of greater celandine alkaloids NSC 631570

Joint Event on 11^th International Conference and Exhibition on Pharmacology and Ethnopharmacology & International Conference on Pharmaceutical Oncology

July 18-19, 2018 | Atlanta, USA

Wassil Nowicky

Ukrainian Anti-Cancer Institute, Austria

Scientific Tracks Abstracts: Clin Exp Pharmacol

Abstract:

It is well known that all cells possess the negative charge and cancer cells have a much more nega-tive charge than normal cells. This property has been used for the creation of the anticancer prepara-tion on basis of greater celandine alkaloids with the positive charge. The experiment has been car-ried out on basis of the sum of greater celandine alkaloids as well as on basis of the pure chelidonine with the aim to understand the mechanism of action of the preparation NSC 631570. Chelidonine is the tertiary alkloid and due to it doesn�??t have the property to fluoresce. After its transformation into the quartet alkaloid it becomes a proton, accumulate in cancer tumors very fast which is visible thanks to its auto fluorescence. Until now this preparation has been tested on over 100 cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at the National Cancer Institute (the USA)) have shown that the NSC 631570 killed only cancer cells without having damaged the normal cells which confirmed its selective effect. In clinical trials it also has proved its anticancer efficacy and caused no noteworthy side effects. The results of in-vitro studies also have shown the direct dele-tion of cancer cells and its ability to regenerate the immune system. Such a property is unusual for an anticancer agent but as it can be seen the NSC 631570 possesses some distinct immune proper-ties. In several immune target-effector systems NSC 631570 significantly amplified the malignotox-ic activity of macrophages, lymphocytes and NK cells, and stimulates dendritic cells maturation in-vitro. While the parameters like B-lymphocytes count, immune globulin concentrations, complement and acute phase proteins did not changed significantly, it can be postulated NSC 631570 modulates the cellular part of the immune system whereas the humoral part remains unaffected. The aim of the presentation is to pay attention on the scientific world on the selective and immunomodulating effects of the very first proton anticancer preparation NSC 631570.

Biography :

Wassil Nowicky Diploma Ing., Dr techn., DDDr HC, Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Inventor of the anticancer preparation on basis of celandine alkaloids “NSC-631570”. Author of over 300 scientific articles dedicated to cancer research. Dr Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.

E-mail: dr.nowicky@yahoo.de